Regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer: an open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603)
Authors
HaraH1
FukuokaS2
TakahashiN3
KojimaT4
KawazoeA5
AsayamaM6
YoshiiT1
KotaniD7
TamuraH5
MikamotoY5
SugamaA8
WakabayashiM9
NomuraS10
SatoA10
TogashiY2
NishikawaH2
ShitaraK11
Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan
Division of Cancer Immunology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Hospital East, Kashiwa, JapanDepartment of Gastroenterology, Saitama Cancer Center, Kitaadachi, JapanNational Cancer Center Hospital East, Kashiwa, JapanNational Cancer Center Hospital East, Kashiwa-shi, JapanSaitama Cancer Center, Saitama, JapanDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, JapanNational Cancer Center, Kashiwa, JapanClinical Research Support Office, National Cancer Center Hospital East, Kashiwa, JapanClinical Research Support Office, National Cancer Center Hospital East, Kashiwa-city, JapanNational Cancer Center, Kashiwa, Japan